NMTC insider files Form 144 to sell 30,000 shares via Edward Jones

Rhea-AI Filing Summary

NeuroOne Medical Technologies (NMTC) filed a Form 144 disclosing a proposed sale of 30,000 common shares through Edward Jones with an aggregate market value of $24,210. The filing lists 49,817,835 shares outstanding and an approximate sale date of 08/20/2025. The shares were acquired on 07/01/2025 as an award from NeuroOne Medical Technologies; the record shows 622,000 shares were acquired on that date and payment/nature is indicated as awarded. The filer reports no securities sold in the past three months and affirms they are not aware of undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Insider plans a small, disclosed sale of awarded shares; appears routine and compliant.

The filing notifies the market of a proposed sale of 30,000 common shares via a broker, with an indicated aggregate value of $24,210 and an approximate sale date of 08/20/2025. The securities were recently acquired as an award on 07/01/2025 and no other sales were reported in the prior three months. This is a standard Form 144 disclosure that provides transparency for an insider disposition; the amounts reported are modest relative to the total shares outstanding.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 notice objectives; includes required representation about material nonpublic information.

The document includes the required representation that the selling person does not possess undisclosed material adverse information and records acquisition details showing the shares were awarded. The filing identifies the broker and provides the approximate sale date. From a governance perspective, the notice appears complete for Rule 144 purposes, documenting the origin of the shares and confirming no prior sales in the last three months.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Edward Jones 201 Progress Parkway Maryland Heights MO 63043	30000	24210.00	49817835	08/20/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/01/2025	Awarded	NeuroOne Med Techologies			622000	07/01/2025	Awarded

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does NeuroOne (NMTC) disclose in this Form 144?

The filing discloses a proposed sale of 30,000 common shares through Edward Jones with an aggregate market value of $24,210 and an approximate sale date of 08/20/2025.

When and how were the shares being sold acquired?

The shares were acquired on 07/01/2025 as an award from NeuroOne Medical Technologies; the filing notes 622,000 shares were acquired on that date.

Does the filing report any sales by the seller in the last three months?

No. The Form 144 states Nothing to Report for securities sold during the past three months.

Which broker is handling the proposed sale?

The proposed sale is listed to be conducted through Edward Jones at the address provided in the filing.

Does the filer assert they have undisclosed material information about NMTC?

By signing the notice, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.